CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Losartan Potassiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03029091
NCT03029091Phase 2Completed
CompareCT.gov

A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder

Children's Hospital Medical Center, Cincinnati·interventional·Posted Jan 24, 2017·Updated Sep 9, 2020

In Brief

A Phase 2 clinical trial evaluating Losartan Potassium for Eosinophilic Esophagitis. Completed, enrolled 15 participants across 3 sites.

Detailed Summary

The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), Office of Rare Diseases (ORD), National Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 24, 2017
Enrollment StartMay 23, 2017
Primary CompletionJul 22, 2019
Study CompletionAug 22, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.4 years ago

Interventions

Losartan Potassiumdrug

Losartan potassium